TNFRSF9 and lymphoma: 4-1BB agonistic antibodies in combination with rituximab, a CD20 monoclonal antibody, have been studied in the treatment of lymphomas and leukemias where they demonstrated clinical benefit with 4-1BB stimulation on NK cells promoting their activation and expansion as well as the ADCC in response to rituximab administration (95).